Mixed Dyslipidemia
📧 Sign up to get email alerts when something new happens for Mixed Dyslipidemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [Phase 4]
Phase 4 clinical trial in India evaluating the safety and effectiveness of inclisiran sodium for primary hypercholesterolemia or mixed dysli…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
A clinical trial evaluating bempedoic acid in combination with ezetimibe and either rosuvastatin or atorvastatin in people with primary hype…
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
This clinical trial evaluates bempedoic acid alone or in a fixed-dose single-pill combination with ezetimibe for primary hypercholesterolemi…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia
Clinical trial update on treatment with bempedoic acid and its fixed-dose combination with ezetimibe for primary hypercholesterolemia and mi…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events [Phase 3]
Phase 3 study evaluating a combination of bempedoic acid, ezetimibe, and a high-intensity statin in patients without cardiovascular events; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-11FDA Approved: FENOFIBRIC ACID — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for Fenofibric acid by Alembic Pharmaceuticals Limited.
-
CLINICAL_TRIALS trial_result · 2026-03-06Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A [Phase 3]
A Phase 3 trial evaluated the combination DW5421A/DW5421B versus DW5421A monotherapy for primary hypercholesterolemia and mixed dyslipidemia…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia [Phase 3]
A Phase 3 clinical trial update for QLC7401 monotherapy in primary hypercholesterolemia or mixed dyslipidemia, sponsored by Qilu Pharmaceuti…
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia [Phase 2]
Phase 2 study evaluating Plozasiran (ARO-APOC3) in adults with mixed dyslipidemia has completed, and results have been posted.
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients
A completed real-world study assessing the effectiveness of inclisiran and PCSK9 monoclonal antibodies in Chinese adults with hypercholester…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3 [NA]
The ATLANTIS trial compares phospholipid omega-3 to conventional omega-3 in adults with mixed dyslipidemia. The study status is not yet recr…
-
CLINICAL_TRIALS research · 2026-02-03Clinical Trial Update: Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Novartis is conducting a clinical trial evaluating LDL-C changes and adherence to inclisiran in a population including primary hypercholeste…
-
FDA approval · 2026-01-21FDA Approved: FENOFIBRATE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved Macleods Pharmaceuticals Limited's fenofibrate under an Original Application (ANDA 210379). The approval permits the generic fe…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study in Patients With Mixed Dyslipidemia [Phase 2]
This is a Phase 2 clinical trial addressing mixed dyslipidemia that is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-01-06Clinical Trial Update: Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers [Phase 1]
Phase 1 study evaluating the safety, pharmacokinetics, and the effect of food on DW5124 and DW5124-R in healthy volunteers has completed.
-
CLINICAL_TRIALS other · 2025-12-22Clinical Trial Update: Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
This is a regulatory post-marketing surveillance study in Korea for Leqvio (inclisiran) in patients with primary hypercholesterolemia or mix…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia [Phase 2]
This update reports the completion of a Phase II study evaluating the safety and efficacy of SAL003 in combination with atorvastatin for hyp…
-
CLINICAL_TRIALS trial_result · 2025-12-08Clinical Trial Update: A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan [Phase 4]
This Phase 4 clinical trial evaluating the effectiveness and safety of bempedoic acid in adults with primary hypercholesterolemia or mixed d…
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A [Phase 1]
Phase 1 study to compare pharmacokinetics and safety between AD-117 and AD-117A in mixed dyslipidemia.
-
CLINICAL_TRIALS trial_result · 2025-11-28Clinical Trial Update: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia [Phase 3]
A multicenter, randomized Phase III trial evaluated SAL003 in combination with statin therapy for hyperlipidemia and mixed dyslipidemia and …
-
FDA approval · 2025-10-01FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Fenofibrate submitted by Lupin Pharmaceuticals, Inc., indicating a regulatory change to this…
-
CLINICAL_TRIALS research · 2025-09-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
Recruiting update for a fixed-dose combination of pitavastatin and ezetimibe to evaluate efficacy and safety in primary hypercholesterolemia…
-
FDA approval · 2025-08-28FDA Approved: FENOFIBRATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' supplemental application for fenofibrate, authorizing continued marketing of fenofibrate for lipid-…
-
FDA approval · 2025-08-21FDA Approved: FENOFIBRATE — Supplemental Application (AvKARE)
FDA approved a supplemental application for Fenofibrate by AvKARE. This approval supports the generic product's marketing under an approved …
-
FDA approval · 2025-08-21FDA Approved: FENOFIBRATE — Supplemental Application (Cipla USA Inc.)
FDA approved a supplemental application for fenofibrate filed by Cipla USA Inc. under the ANDA 208709.